Get started
Author

Matthew A. Lakins

Observed names: M.A. LAKINS, M.A. Lakins, Matthew Lakins
ORCID: 0000-0001-7098-9166
Observed ORCID: 0000-0001-7098-9166
OpenAlex ID: A5032095536
Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells
2018 · Matthew A. Lakins, Ehsan Ghorani, et al. · Nature Communications · 601
PDF
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2020 · Matthew A. Lakins, Alexander Koers, et al. · Clinical Cancer Research · 66
Exploiting advances in imaging technology to study biofilms by applying multiphoton laser scanning microscopy as an imaging and manipulation tool
2009 · M.A. LAKINS, J.L. MARRISON, et al. · Journal of Microscopy · 10
PDF
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al. · Cancer Research Communications · 8
PDF
Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al. · 1
173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors
2022 · G.A. De Velasco Oria, E. Garralda, et al. · Immuno-Oncology Technology · 1
165TiP A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies
2021 · E. Garralda, I. Melero, et al. · Annals of Oncology · 1
573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies
2021 · Matthew Lakins, Wenjia Liao, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 4547: Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation
2020 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Immunology · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Designed for Optimal CD137 Engagement Resulting in Potent Conditional T-Cell Activity
2025 · Matthew A. Lakins, Christel Séguy Veyssier, et al. · Current Cancer Drug Targets
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Figure 6 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Figure 5 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Works count: 40
Citation count: 692
H-index: 4
I10-index: 3
Year
Topic
Type